Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

SHA:600664 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	16,099	16,119	15,400	13,755	12,741	10,741
Other Revenue	59.62	56.83	56.21	53.63	61.06	47.59
Revenue	16,158	16,176	15,457	13,809	12,802	10,788
Revenue Growth (YoY)	1.65%	4.65%	11.93%	7.86%	18.66%	-8.76%
Cost of Revenue	11,830	11,655	11,443	10,446	9,826	8,543
Gross Profit	4,329	4,521	4,013	3,363	2,976	2,245
Selling, General & Admin	3,256	3,390	3,143	2,565	2,306	2,824
Research & Development	143.09	136.43	106.02	115.81	97.73	92.53
Other Operating Expenses	138.56	108.29	120.17	122.65	113.17	104.39
Operating Expenses	3,585	3,671	3,395	2,805	2,528	3,049
Operating Income	744.03	849.71	618.44	557.91	447.79	-803.3
Interest Expense	-53.69	-60.07	-56.47	-85.53	-105.16	-58.27
Interest & Investment Income	33.49	49.47	51.58	69.19	16.5	50.42
Currency Exchange Gain (Loss)	-6.95	-5.68	-5.37	3	1.99	-0.83
Other Non Operating Income (Expenses)	60.09	66.61	-22.74	-19.44	-5.07	-176.52
EBT Excluding Unusual Items	776.95	900.04	585.45	525.13	356.06	-988.49
Gain (Loss) on Sale of Investments	-	-	-	-20	-	-
Gain (Loss) on Sale of Assets	4.64	0.94	0.98	161.38	210.87	14.1
Asset Writedown	-59.84	-59.84	-15.13	-32.52	-2.33	-74.72
Other Unusual Items	45.65	33.87	79.25	67.17	65.93	80.47
Pretax Income	767.4	875.01	650.54	701.15	630.53	-968.65
Income Tax Expense	176.07	184.4	176.32	188.94	220.69	76.6
Earnings From Continuing Operations	591.33	690.61	474.22	512.21	409.85	-1,045
Minority Interest in Earnings	-46.17	-61.76	-78.95	-47.06	-38.76	-32.45
Net Income	545.17	628.85	395.26	465.15	371.08	-1,078
Net Income to Common	545.17	628.85	395.26	465.15	371.08	-1,078
Net Income Growth	-1.94%	59.10%	-15.02%	25.35%	-	-
Shares Outstanding (Basic)	2,588	2,515	2,470	2,448	2,474	2,506
Shares Outstanding (Diluted)	2,588	2,515	2,470	2,584	2,474	2,506
Shares Change (YoY)	8.19%	1.82%	-4.40%	4.46%	-1.29%	-10.19%
EPS (Basic)	0.21	0.25	0.16	0.19	0.15	-0.43
EPS (Diluted)	0.21	0.25	0.16	0.18	0.15	-0.43
EPS Growth	-9.36%	56.25%	-11.11%	20.00%	-	-
Free Cash Flow	467.08	691.69	863.14	532.45	-239.13	-846.37
Free Cash Flow Per Share	0.18	0.28	0.35	0.21	-0.10	-0.34
Gross Margin	26.79%	27.95%	25.96%	24.35%	23.24%	20.81%
Operating Margin	4.61%	5.25%	4.00%	4.04%	3.50%	-7.45%
Profit Margin	3.37%	3.89%	2.56%	3.37%	2.90%	-9.99%
Free Cash Flow Margin	2.89%	4.28%	5.58%	3.86%	-1.87%	-7.85%
EBITDA	943.31	1,066	878.27	821.32	716.99	-433.54
EBITDA Margin	5.84%	6.59%	5.68%	5.95%	5.60%	-4.02%
D&A For EBITDA	199.28	216.29	259.83	263.41	269.2	369.75
EBIT	744.03	849.71	618.44	557.91	447.79	-803.3
EBIT Margin	4.61%	5.25%	4.00%	4.04%	3.50%	-7.45%
Effective Tax Rate	22.94%	21.07%	27.10%	26.95%	35.00%	-
Revenue as Reported	16,158	16,176	15,457	13,809	12,802	10,788
Advertising Expenses	-	1,806	1,574	1,058	340.89	201.29

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.